Avalo Therapeutics Inc
Ownership
Ownership Structure
Who owns Avalo Therapeutics Inc (AVTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.8% of the shares are freely tradable; institutional investors hold 76.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Deep Track Capital, LP | 6.73 | 3,610,000 | +0.0 | 06/30/2026 |
| Caligan Partners LP | 5.90 | 3,163,866 | +93.5 | 06/30/2026 |
| TCG Crossover Management, LLC | 5.63 | 3,017,120 | +308.6 | 06/30/2026 |
| Affinity Asset Advisors, LLC | 5.41 | 2,900,000 | +116.3 | 06/30/2026 |
| FMR Inc | 5.37 | 2,879,481 | +1,207.1 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 4.03 | 2,162,684 | +0.0 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 3.22 | 1,729,000 | +102.5 | 06/30/2026 |
| Soleus Capital Management, L.P. | 3.09 | 1,654,978 | +274.4 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.99 | 2,141,539 | -1.1 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.12 | 1,675,498 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer | 51,776 | 864,659 $ | Aug 28, 2026 | direct |
| Sullivan Christopher Ryan | Chief Financial Officer | 39,900 | 666,330 $ | Sep 10, 2026 | direct |
| Riley Jennifer | Chief Strategy Officer | 37,041 | 618,585 $ | Aug 11, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 10,185 | 17.62 | 179,457 |
| Sep 10, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 10,185 | 8.04 | 81,887 |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 679 | 20.00 | 13,580 |
| Aug 28, 2026 | Doyle Mittie | Chief Medical Officer | Other | 679 | 8.04 | 5,459 |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 31,031 | 20.05 | 622,324 |
| Aug 18, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 31,031 | 9.88 | 306,586 |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 1,000 | 20.00 | 20,000 |
| Aug 17, 2026 | Doyle Mittie | Chief Medical Officer | Other | 1,000 | 12.65 | 12,650 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 3,749 | 19.94 | 74,762 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 37,945 | 19.85 | 753,333 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 2,876 | 9.88 | 28,415 |
| Aug 17, 2026 | Sullivan Christopher Ryan | Chief Financial Officer | Other | 37,945 | 9.88 | 374,897 |
| Aug 11, 2026 | Riley Jennifer | Chief Strategy Officer | Sell | 2,655 | 19.59 | 52,012 |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 679 | 20.00 | 13,580 |
| Aug 10, 2026 | Doyle Mittie | Chief Medical Officer | Other | 679 | 8.04 | 5,459 |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | Sell | 1,000 | 20.00 | 20,000 |
| Jul 27, 2026 | Doyle Mittie | Chief Medical Officer | Other | 1,000 | 12.65 | 12,650 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.